Tidefast
KordlessKaimenBlogLeadershipPressContact中文
KordlessKaimenBlogLeadershipPressContact中文
Product

Kaimen

Patients facing terminal diagnoses don't always lack options - they lack knowledge that options exist. Kaimen distributes medical intelligence and turns it into actionable access.

I need...

CAR-T CELL THERAPY

Access to China's six approved CAR-T treatments, including the world's first solid-tumor CAR-T. The same therapy at 35% of US costs - for patients told there are no options left.

kaimen.co/car-t
↗
CLINICAL TRIALS

China runs more CAR-T trials than any country. For patients who don't qualify for approved therapies, Kaimen navigates the active trial pipeline across pancreatic, liver, lung, and other cancers.

kaimen.co/trials
↗
MEDICAL CARE

Dental implants, orthopedic surgery, and specialist procedures at 25-30% of Western costs. Lower stakes, higher volume, same standard of care.

kaimen.co/care
↗
← Back home
© 2026 Tidefast LimitedDistributed Intelligence